A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).

被引：0

作者：

Richardson, Paul G.

Attal, Michel

Rajkumar, S. Vincent

San Miguel, Jesus

Beksac, Meral

Spicka, Ivan

Leleu, Xavier

Schjesvold, Fredrik

Moreau, Philippe

Dimopoulos, Meletios A.

Huang, Jeffrey S. Y.

Minarik, Jiri

Cavo, Michele

Prince, H. Miles

Mace, Sandrine

Corzo, Kathryn Penkus

Campana, Frank

Le-Guennec, Solenn

Dubin, Franck

Anderson, Kenneth Carl

机构：

[1] Harvard Med Sch, Jerome Lipper Multiple Myeloma Ctr, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA

[2] IUCT Oncopole, Toulouse, France

[3] Mayo Clin, Rochester, MN USA

[4] Clin Univ Navarra, Navarra, Spain

[5] Ankara Univ, Ankara, Turkey

[6] Vseobecna Fak Nemocnice V Praze, Prague, Czech Republic

[7] CHRU Lille, Lille, France

[8] Oslo Univ Hosp, Oslo, Norway

[9] CHU Nantes, Hotel Dieu, Nantes, France

[10] Univ Athens, Athens, Greece

[11] Natl Taiwan Univ Hosp, Taipei, Taiwan

[12] Univ Hosp Olomouc, Olomouc, Czech Republic

[13] Bologna Univ, Sch Med, Seragnoli Inst Hematol, Bologna, Italy

[14] Epworth Healthcare, Melbourne, Vic, Australia

[15] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[16] Sanofi R&D, Oncol, Vitry Sur Seine, France

[17] Sanofi, Cambridge, MA USA

[18] Sanofi US, Cambridge, MA USA

[19] Sanofi R&D, Vitry Sur Seine, France

[20] Sanofi, Vitry Sur Seine, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8004

引用

页数：2

共 50 条

[41] Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World "POWERFUL" Study
Terpos, Evangelos
Repousis, Panagiotis
Lalayanni, Chrysavgi
Hatjiharissi, Evdoxia
Assimakopoulou, Theodora
Vassilopoulos, Georgios
Pouli, Anastasia
Spanoudakis, Emmanouil
Michalis, Eurydiki
Pangalis, Gerassimos
Ntanasis-Stathopoulos, Ioannis
Poziopoulos, Christos
Kyrtsonis, Marie-Christine
Pappa, Vasiliki
Symeonidis, Argiris
Georgopoulos, Christos
Zikos, Panagiotis M.
Gavriatopoulou, Maria
Papadaki, Helen A.
Dadakaridou, Magdalini
Karvounis-Marolachakis, Kiki
Katodritou, Eirini
JOURNAL OF CLINICAL MEDICINE, 2021, 10 (07)
[42] Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial
Huixing Zhou
Yafei Wang
Jiao Chen
Aili He
Jie Jin
Quanyi Lu
Ying Zhao
Junjun Li
Ming Hou
Liping Su
Xun Lai
Wei Wang
Lihong Liu
Yanping Ma
Da Gao
Wenhong Lai
Xin Zhou
Hongmei Jing
Jinqiao Zhang
Wei Yang
Xuehong Ran
Congmeng Lin
Jianping Hao
Taiwu Xiao
Zhenqian Huang
Zhigang Zhu
Qing Wang
Baijun Fang
Binghua Wang
Yanping Song
Zhen Cai
Bo Liu
Yanan Zhu
Xinai Yang
Xiaoyan Kang
Juan Li
Wenming Chen
Annals of Hematology, 2024, 103 : 855 - 868
[43] Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma
Weisel, Katja
Dimopoulos, Meletios
Moreau, Philippe
Yagci, Munci
Larocca, Alessandra
Kanate, Abraham S.
Vural, Filiz
Cascavilla, Nicola
Basu, Supratik
Johnson, Peter
Byeff, Peter
Hus, Marek
Rodriguez-Otero, Paula
Muelduer, Ercan
Anttila, Pekka
Hayden, Patrick J.
Krauth, Maria-Theresa
Lucio, Paulo
Ben-Yehuda, Dina
Mendeleeva, Larisa
Guo, Shien
Yu, Xin
Grote, Lara
Biyukov, Tsvetan
Dhanasiri, Sujith
Richardson, Paul
LEUKEMIA & LYMPHOMA, 2020, 61 (08) : 1850 - 1859
[44] Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
Dimopoulos, Meletios A.
Weisel, Katja C.
Song, Kevin W.
Delforge, Michel
Karlin, Lionel
Goldschmidt, Hartmut
Moreau, Philippe
Banos, Anne
Oriol, Albert
Garderet, Laurent
Cavo, Michele
Ivanova, Valentina
Alegre, Adrian
Martinez-Lopez, Joaquin
Chen, Christine
Spencer, Andrew
Knop, Stefan
Bahlis, Nizar J.
Renner, Christoph
Yu, Xin
Hong, Kevin
Sternas, Lars
Jacques, Christian
Zaki, Mohamed H.
San Miguel, Jesus F.
HAEMATOLOGICA, 2015, 100 (10) : 1327 - 1333
[45] Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial
Zhou, Huixing
Wang, Yafei
Chen, Jiao
He, Aili
Jin, Jie
Lu, Quanyi
Zhao, Ying
Li, Junjun
Hou, Ming
Su, Liping
Lai, Xun
Wang, Wei
Liu, Lihong
Ma, Yanping
Gao, Da
Lai, Wenhong
Zhou, Xin
Jing, Hongmei
Zhang, Jinqiao
Yang, Wei
Ran, Xuehong
Lin, Congmeng
Hao, Jianping
Xiao, Taiwu
Huang, Zhenqian
Zhu, Zhigang
Wang, Qing
Fang, Baijun
Wang, Binghua
Song, Yanping
Cai, Zhen
Liu, Bo
Zhu, Yanan
Yang, Xinai
Kang, Xiaoyan
Li, Juan
Chen, Wenming
ANNALS OF HEMATOLOGY, 2024, 103 (03) : 855 - 868
[46] Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study
Sara Bringhen
Roberto Mina
Anna Maria Cafro
Anna Marina Liberati
Stefano Spada
Angelo Belotti
Gianluca Gaidano
Francesca Patriarca
Rossella Troia
Renato Fanin
Lorenzo De Paoli
Giuseppe Rossi
Alessandra Lombardo
Paola Bertazzoni
Antonio Palumbo
Pieter Sonneveld
Mario Boccadoro
Leukemia, 2018, 32 : 1803 - 1807
[47] Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study
Bringhen, Sara
Mina, Roberto
Cafro, Anna Maria
Liberati, Anna Marina
Spada, Stefano
Belotti, Angelo
Gaidano, Gianluca
Patriarca, Francesca
Troia, Rossella
Fanin, Renato
De Paoli, Lorenzo
Rossi, Giuseppe
Lombardo, Alessandra
Bertazzoni, Paola
Palumbo, Antonio
Sonneveld, Pieter
Boccadoro, Mario
LEUKEMIA, 2018, 32 (08) : 1803 - 1807
[48] Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
Lacy, Martha Q.
Hayman, Suzanne R.
Gertz, Morie A.
Dispenzieri, Angela
Buadi, Francis
Kumar, Shaji
Greipp, Philip R.
Lust, John A.
Russell, Stephen J.
Dingli, David
Kyle, Robert A.
Fonseca, Rafael
Bergsagel, P. Leif
Roy, Vivek
Mikhael, Joseph R.
Stewart, A. Keith
Laumann, Kristina
Allred, Jacob B.
Mandrekar, Sumithra J.
Rajkumar, S. Vincent
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (30) : 5008 - 5014
[49] Pomalidomide plus low-dose dexamethasone (POM plus LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): Impact of cytogenetics in MM-003
Goldschmidt, Hartmut
Dimopoulos, Meletios A.
Weisel, Katja C.
Moreau, Philippe
Lacy, Martha
Song, Kevin W.
Delforge, Michel
Karlin, Lionel
Banos, Anne
Rocafiguera, Albert Oriol
Yu, Xin
Sternas, Lars
Jacques, Christian
Zaki, Mohamed H.
San-Miguel, Jesus F.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[50] Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial
Dimopoulos, Meletios
Weisel, Katja
van de Donk, Niels W. C. J.
Ramasamy, Karthik
Gamberi, Barbara
Streetly, Matthew
Offidani, Massimo
Bridoux, Frank
de la Rubia, Javier
Mateos, Maria-Victoria
Ardizzoia, Antonio
Kueenburg, Elisabeth
Collins, Shona
Di Micco, Antonia
Rosettani, Barbara
Li, Yan
Bacon, Pamela
Sonneveld, Pieter
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (20) : 2035 - +

← 1 2 3 4 5 →